NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 1997
Business Overview: The Company formulates and produces encapsulated vitamins, nutrients, and nutritional supplements. It provides marketing services, foreign registration assistance, and graphic design to clients, primarily large, global companies. In fiscal 1997, the Company expanded its manufacturing capacity by adding a tablet facility and transferred the operations of two wholly-owned subsidiaries (Millennium Health Products and CellLife International) to the parent company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 3.8% ($1.8 million) driven by increased sales to existing customers, despite a decline in international sales from $4.3 million to $1.9 million due to a major client restructuring in Europe.
• Profitability Decline: Income from operations decreased 65.5% to $1.8 million. This was caused by a $2.0 million drop in gross profit and a $1.4 million increase in selling, general, and administrative (SG&A) expenses.
• Margin Compression: Gross profit margins fell from 26.1% to 21.1%. Contributing factors included a shift in product mix toward lower-margin items, rising raw material costs, increased subcontracted packaging costs, and write-offs of obsolete raw materials and packaging.
• Expense Increases: SG&A expenses rose to $8.6 million (17.4% of sales) from $7.2 million (15.1% of sales). Increases were attributed to a specific provision for doubtful accounts from a related party, costs for clinical studies, write-offs of marketing fixtures, and startup costs for the new tablet facility.
• Cash Flow Improvement: Net cash provided by operating activities surged to $3.8 million from $1.1 million, primarily due to an increase in accounts payable and a decrease in inventory, offsetting lower net earnings.

Outlook, Risks, and Management Commentary

• Backlog: As of September 22, 1997, the backlog was $18.1 million, a significant increase from $12.5 million the prior year, attributed to customer expansion into foreign markets.
• Capital Expenditures: The Company spent $2.2 million in 1997 on a new tablet facility. It anticipates spending approximately $1.5 million in fiscal 1998 for equipment and building improvements.
• Liquidity: The Company maintains $3.0 million in revolving lines of credit with no borrowings outstanding as of June 30, 1997. Management believes current resources are sufficient for anticipated funding requirements.
• Customer Concentration Risk: Three customers (Nu Skin International, NSA International, and Nutrilite Products) represented 62% of sales in 1997. The loss of any of these customers could have a material adverse impact.
• Regulatory Environment: Operations are subject to FDA, FTC, and other regulations regarding labeling, advertising, and safety. The Company conforms to United States Pharmacopeia (USP) specifications.
• Related Party Transactions: The Company has significant related party transactions, including loans to the CEO and President, commissions paid to the CEO's in-laws, and a recent purchase of a building previously leased from principal stockholders.

Investor Verification Checklist

• Customer Concentration: Verify the stability of relationships with the top three customers who comprise 62% of revenue.
• Related Party Receivables: Review the $775,000 receivable from a related party that was fully reserved as doubtful in 1997.
• Margin Sustainability: Assess whether the decline in gross margins (21.1%) is a temporary anomaly or a structural shift due to product mix and raw material costs.
• Debt Covenants: Confirm continued compliance with financial covenants on the $3.0 million line of credit expiring December 1997.
• Capital Expenditure ROI: Monitor the utilization and revenue generation of the new tablet manufacturing facility.